Biotech veterans with a track record of success may be just months away from marketing the first drug to treat heart failure by genetically identifying patients for whom the drug would work. The drug, an experimental beta blocker named “bucindolol” that’s been studied for more than 20 years, could be a milestone in the long-sought niche of personalized medicine.
